Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: ESMO Open, 7, 5, S. 100576-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2022
- Ereignis
-
Veröffentlichung
- (wer)
-
Elsevier BV
- (wann)
-
2022
- Urheber
-
Le Tourneau, C.
Becker, H.
Claus, Rainer
Elez, E.
Ricci, F.
Fritsch, R.
Silber, Yvonne
Hennequin, A.
Tabernero, J.
Jayadeva, G.
Luedtke, D.
He, M.
Isambert, N.
- DOI
-
10.1016/j.esmoop.2022.100576
- URN
-
urn:nbn:de:bvb:384-opus4-986713
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Le Tourneau, C.
- Becker, H.
- Claus, Rainer
- Elez, E.
- Ricci, F.
- Fritsch, R.
- Silber, Yvonne
- Hennequin, A.
- Tabernero, J.
- Jayadeva, G.
- Luedtke, D.
- He, M.
- Isambert, N.
- Universität Augsburg
- Elsevier BV
Entstanden
- 2022
Ähnliche Objekte (12)
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
React: recognize every action everywhere all at once
Once
ONCe
once
ONCE
ONCE
once
Once
Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
Escena once
ONCE "OKC"
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
React: recognize every action everywhere all at once
Once
ONCe
once
ONCE
ONCE
once
Once
Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
Escena once
ONCE "OKC"
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
React: recognize every action everywhere all at once
Once
ONCe
once
ONCE
ONCE
once
Once
Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
Escena once